EndoGastric Solutions, Inc. Announces RESPECT Trial Exceeds Enrollment Target

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN MATEO, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that enrollment for the RESPECT study (Randomized EsophyX® vs. Sham/Placebo Controlled Trial) is complete and has surpassed the company’s original target of 120 patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news